Biotechnology company CytoDyn Inc. (CYDY.OB) announced Monday that it has provided its Top-line Report from its recently completed, randomized, double-blind, Phase 2 trial for COVID-19 patients in the U.S. with mild-to-moderate symptoms to the U.S. Food and Drug Administration (FDA), and requested emergency use approval.
from RTT - Biotech https://ift.tt/30ZWkFg
via IFTTT
No comments:
Post a Comment